Monday, September 24th, 2007 - Pemextrexed Shows Promise in Peritoneal Mesothelioma: Presented at ECCO
Archive for the 'Eli Lilly' Category
Thursday, September 20th, 2007 - Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Thursday, December 7th, 2006 - Lilly Delivers Promising Update to Wall Street on Strategic Priorities, Pipeline Progress and Earnings Guidance
Monday, September 11th, 2006 - Oncology Researchers Recognized as Heroes of Chemistry; American Chemical Society Honors Lilly and Princeton Scientists for Discovery of Therapy for Asbestos-Related Cancer
Sunday, June 4th, 2006 - Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta(R) and Docetaxel; Alimta Also Shows Tolerability as Triplet Combination Treatment in First-Line Lung Cancer
Tuesday, May 23rd, 2006 - Lilly Oncology Prepares for Strong Showing at ASCO 2006; Targets Breast Cancer and Other Tumors with 79 Studies: 11 breast cancer studies; 29 thoracic cancer studies; and 8 studies with developing targeted agent
Tuesday, July 5th, 2005 - Thoracic Cancer Patients Find New Reasons for Hope with Alimta®: New data may provide important treatment advances in mesothelioma and lung cancer
Monday, November 1st, 2004 - Alimta Approved as First Licensed Treatment for Mesothelioma, a Deadly Cancer Caused by Asbestos
Thursday, August 19th, 2004 - FDA Approves Lilly’s Alimta(R) (pemetrexed) for the Second-Line Treatment of Advanced Lung Cancer: Accelerated Approval Results in Second U.S. Indication in Six Months for Alimta
Thursday, July 22nd, 2004 - Alimta(R) Receives Positive Endorsement for Lung Cancer Approval from FDA Advisory Committee; Unanimous Endorsement for Accelerated Approval in Second-Line Non-Small Cell Lung Cancer
Thursday, June 24th, 2004 - Alimta® Receives CHMP Positive Opinion for Two Cancer Indications: Recommended for Approval to Treat Malignant Pleural Mesothelioma and Lung Cancer
